United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,139,832.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $316.62, for a total value of $1,139,832.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,160.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $318.55 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The firm has a market cap of $14.13 billion, a price-to-earnings ratio of 15.06, a price-to-earnings-growth ratio of 1.40 and a beta of 0.49. The firm’s fifty day moving average price is $274.77 and its 200 day moving average price is $243.95. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $321.80.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company’s revenue was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.86 EPS. On average, sell-side analysts expect that United Therapeutics Co. will post 24.73 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on UTHR shares. HC Wainwright reiterated a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research note on Thursday, May 2nd. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, June 12th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Finally, JPMorgan Chase & Co. upped their target price on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $312.22.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. International Assets Investment Management LLC raised its position in shares of United Therapeutics by 13,769.2% during the 4th quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock worth $1,982,000 after purchasing an additional 8,950 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of United Therapeutics by 54.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock valued at $20,617,000 after acquiring an additional 33,338 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of United Therapeutics by 155.2% in the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock valued at $8,427,000 after acquiring an additional 23,532 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of United Therapeutics by 90.3% during the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock valued at $12,200,000 after acquiring an additional 26,325 shares during the last quarter. Finally, Duality Advisers LP increased its position in United Therapeutics by 56.1% during the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock worth $3,440,000 after purchasing an additional 5,622 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.